Home  Contact Us
  Follow Us On:
Advertising Advertising Free Newsletter Free E-Newsletter

BioNTech to evaluate mixing vaccines as China enters final phase in approving mRNA shots
Published on: 2021-04-30
Share to
User Rating: / 0

China's potential approval of BioNTech's mRNA COVID-19 vaccine has entered the final stage in decision-making processes, and the conversation with Chinese authorities is very "encouraging," German-based vaccine developer BioNTech's CEO Ugur Şahin said on Thursday, with strong confidence for China's marketing prospects of the mRNA vaccine co-developed with Shanghai-based Fosun Pharma.

The co-founder of BioNTech, Ugur Sahin, says the arrival of China's first foreign-developed COVID-19 vaccine "is very likely" as early as July.

BioNTech has been working with local partners in China since last December to deliver 100 million doses this year, with approval for the formula from the Chinese authorities still pending.

In an interview, the co-founder of the German pharmaceutical firm – which has been at the forefront of the global medical response to the coronavirus with its vaccine produced with U.S. giant Pfizer – said: "I am optimistic that we can help the people of China."

Sahin added that the Shanghai Fosun Pharmaceutical Group had proved to be "a great company" to work with.

China is known to be keen to add a range of globally produced vaccines to its five most popular domestic treatments, partly to ease the return to international travel in the post-pandemic recovery period.

Comments (0)Add Comment

Write comment

security code
Write the displayed characters

    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2021 BusinessTianjin.com. All rights reserved.